USPTO Examiner LI RUIXIANG - Art Unit 1674

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19333265Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) AntibodiesSeptember 2025March 2026Allow610NoNo
19267411COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJuly 2025August 2025Allow100NoNo
19056312PD1 AND VEGFR2 DUAL-BINDING AGENTSFebruary 2025October 2025Allow811NoNo
18881999ANTIBODY, NUCLEIC ACID, CELL, AND PHARMACEUTICALJanuary 2025February 2026Allow1311YesNo
18989629ZIP12 ANTIBODYDecember 2024July 2025Allow601NoNo
18955328ANTI-TUMOR PHARMACEUTICAL COMPOSITION BASED ON IMMUNE CHECKPOINT BLOCKADE AND USE THEREOFNovember 2024January 2026Allow1431YesNo
18929510METHODS FOR THE TREATMENT OF THYROID EYE DISEASEOctober 2024February 2025Allow410YesNo
18859969TARGETED ANTI-SGLT1 AVIAN IGY ANTIBODIES AS TREATMENT OF PRE-DIABETES, TYPE 2 DIABETES AND GESTATIONAL DIABETESOctober 2024November 2025Allow1311NoNo
18883787METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDRSeptember 2024November 2025Abandon1420YesNo
18804738INTERLEUKIN 21 VARIANTSAugust 2024January 2025Allow510NoNo
18790955ANTI-GPRC5D ANTIBODIES AND COMPOSITIONSJuly 2024December 2024Allow401NoNo
18671801TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINMay 2024October 2024Allow510NoNo
18656236IL23R BINDING MOLECULES AND METHODS OF USEMay 2024March 2025Abandon1001NoNo
18656092ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOFMay 2024September 2024Allow501NoNo
18583481ERBB-2 AND ERBB-3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENEFebruary 2024November 2024Allow820NoNo
18431767METHODS OF USING IMMUNOTHERAPEUTICS THAT BIND FOLATE RECEPTOR ALPHAFebruary 2024February 2025Allow1211NoNo
18431734PROTEINS THAT BIND FOLATE RECEPTOR ALPHA INCLUDING FULLY-HUMAN ANTIBODIESFebruary 2024March 2025Allow1421NoNo
18426199HOMODIMERIC ANTIBODIES FOR USE IN TREATING CANCERS AND METHODS OF USEJanuary 2024January 2025Allow1211NoNo
18402604COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJanuary 2024August 2024Allow720NoNo
18562807ANTIBODY OR ANTIBODY FRAGMENT THAT SPECIFICALLY BINDS TO VOLTAGE-GATED SODIUM CHANNEL ALPHA SUBUNIT NAV1.7November 2023December 2025Abandon2501NoNo
18556606ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODYOctober 2023October 2024Allow1211NoNo
18555338HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASEOctober 2023May 2025Allow1921NoNo
18446795ANTIBODIES THAT BIND EGFR AND CMETAugust 2023March 2026Allow3100NoNo
18337737ALK7 Binding Proteins and Uses ThereofJune 2023February 2026Allow3200NoNo
18331422PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODYJune 2023June 2025Allow2510NoNo
18327091TRANSFERRIN BINDING ANTIBODIES AND USE THEREOFJune 2023July 2024Allow1311YesNo
18305158Antibody selection methodApril 2023August 2025Allow2810NoNo
18193030Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses ThereofMarch 2023August 2024Allow1622NoNo
18189065ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHYMarch 2023June 2025Allow2611NoNo
18182242MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2March 2023March 2026Allow3611NoNo
18175894ANTIBODIES BINDING AXLFebruary 2023November 2025Allow3311NoNo
18166994COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOFFebruary 2023September 2025Abandon3101NoNo
18068237Anti-MARCO Antibodies and Uses ThereofDecember 2022April 2025Allow2710NoNo
18082960METHODS AND MATERIALS FOR TREATING CANCERDecember 2022August 2025Abandon3201NoNo
18001689STABLE ANTI-CLEVER-1 ANTIBODY FORMULATIONDecember 2022February 2026Allow3810YesNo
17928979GFRAL-ANTAGONISTIC ANTIBODY AND USE THEREOFDecember 2022July 2025Allow3200NoNo
18058239THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND METHODS FOR USE OF SAMENovember 2022September 2024Allow2200NoNo
17924660ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING ANEMIA OF CHRONIC DISEASENovember 2022January 2026Allow3810NoNo
17924014PROTEIN THAT SIMULTANEOUSLY AND POTENTLY BINDS TO BOTH MCL-1 AND BCL-xL AND USES THEREOFNovember 2022September 2025Allow3510NoNo
18050970RECOMBINANT ANTIBODY HAVING UNIQUE GLYCAN PROFILE PRODUCED BY CHO HOST CELL WITH EDITED GENOME AND PREPARATION METHOD THEREOFOctober 2022March 2026Allow4120YesNo
18050244BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOFOctober 2022August 2025Allow3411NoNo
18047988CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMSOctober 2022January 2025Allow2710NoNo
18046859CD155 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOFOctober 2022October 2025Allow3621NoNo
17918704METHOD FOR PROGNOSIS PREDICTION OF SKIN CANCER AND USE THEREOFOctober 2022January 2026Allow3911YesNo
18046082COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USEOctober 2022February 2025Allow2811NoNo
17916460A PROTEIN COMPLEX COMPRISING AN IMMUNOCYTOKINESeptember 2022January 2026Abandon3910NoNo
17935409Treatment of Respiratory DiseaseSeptember 2022December 2025Abandon3910NoNo
17933709TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTIONSeptember 2022December 2024Allow2610NoNo
17911347SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONSSeptember 2022February 2026Abandon4111NoNo
17942695TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOFSeptember 2022May 2025Allow3220NoNo
17902449ANTIBODIES WHICH BIND TO LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1)September 2022September 2025Allow3701NoNo
17929572TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINSeptember 2022March 2025Abandon3010NoNo
17823824NOTCH3 Agonist Compositions and Methods for Treating Small Vessel DiseasesAugust 2022November 2025Allow3821NoNo
17820785Compositions and Methods for Treating Cancer with Anti-ROR1 ImmunotherapyAugust 2022October 2025Allow3810NoNo
17819161ANTI-IL-22R ANTIBODIESAugust 2022March 2025Abandon3110NoNo
17797720ANTI-C-MET ANTIBODY-DRUG CONJUGATE AND APPLICATIONS THEREOFAugust 2022October 2025Allow3810NoNo
17817295COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIESAugust 2022September 2024Allow2600NoNo
17796375ANTI-G-PROTEIN ALPHA ANTIBODYJuly 2022October 2025Allow3810NoNo
17814434COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERSJuly 2022March 2025Allow3211NoNo
17812256ANTI-GITR ANTIBODIES AND USES THEREOFJuly 2022March 2025Abandon3201NoNo
17758671COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIAJuly 2022December 2025Abandon4101NoNo
17847380TARGETED MODIFIED TNF FAMILY MEMBERSJune 2022October 2024Allow2810NoNo
17808248ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOFJune 2022November 2024Abandon2801NoNo
17846709ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOFJune 2022March 2026Allow4511NoNo
17846845APPARATUS AND METHOD FOR OOCYTE RESCUE IN VITRO POST STIMULATIONJune 2022February 2024Abandon1911NoNo
17831254DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1June 2022March 2025Abandon3311NoNo
17752074METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULINMay 2022March 2025Abandon3401NoNo
17747764GPCR BINDING PROTEINS AND SYNTHESIS THEREOFMay 2022March 2025Abandon3411NoNo
17775574ANTIBODY-PAYLOAD CONJUGATES WITH ENHANCED DELIVERY DOMAIN AND USES THEREOFMay 2022February 2026Allow4511NoNo
17733226Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/Neu (ERBB2) receptor proteinApril 2022July 2025Allow3801NoNo
17733026FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIESApril 2022May 2025Allow3621NoNo
17772344SCREENING METHOD FOR OFFENSIVE ODOR-SUPPRESSING MATERIALApril 2022December 2025Allow4420NoNo
17727432ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOFApril 2022July 2025Allow3921NoNo
17770776NANODISC-SPECIFIC ANTIGEN-BINDING CHIMERIC PROTEINSApril 2022March 2026Allow4721NoNo
17768013PD1 AND VEGFR2 DUAL-BINDING AGENTSApril 2022February 2026Abandon4711NoNo
17704623POPULATIONS OF ENRICHED REGULATORY T CELLS AND METHODS FOR PRODUCING SAMEMarch 2022March 2026Allow4711NoNo
17687934VARIANT ACTRIIB PROTEINS AND USES THEREOFMarch 2022October 2024Allow3111NoNo
17639467ANTI-FUCOSYL-GM1 ANTIBODIESMarch 2022November 2025Allow4510NoNo
17678748T-CELL MODULATORY CHIMERIC MOLECULES AND METHODS OF USE THEREOFFebruary 2022November 2025Abandon4511NoNo
17666705ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOFFebruary 2022November 2024Allow3320NoNo
17632107RELAXIN ANALOGS AND METHODS OF USING THE SAMEFebruary 2022January 2025Allow3611NoNo
17579345ADAMTS Binding ImmunoglobulinsJanuary 2022September 2024Allow3220NoNo
17561448AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIESDecember 2021December 2024Allow3511NoNo
17561496COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING TO TREAT CANCERDecember 2021January 2025Allow3711YesNo
17531365METHODS FOR THE TREATMENT OF THYROID EYE DISEASENovember 2021September 2024Allow3420NoNo
17531368METHODS FOR THE TREATMENT OF THYROID EYE DISEASENovember 2021November 2024Allow3611NoNo
17524883THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITHNovember 2021July 2024Allow3210NoNo
17523226SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOFNovember 2021November 2024Allow3621NoNo
17522600MONOCLONAL ANTI-IL-1RACP ANTIBODIESNovember 2021October 2024Allow3511NoNo
17517370Senescent Cell BiomarkersNovember 2021January 2025Allow3921YesNo
17517045COMPOSITIONS AND METHODS FOR ALLEVIATING PAINNovember 2021January 2026Abandon5011NoNo
17442636MONOCLONAL ANTIBODY AGAINST STIM1September 2021February 2026Abandon5321NoNo
17474718IL1-R1 DERIVED INHIBITOR OF IL-1b AND USE THEREOFSeptember 2021January 2024Abandon2801NoNo
17398294Bispecific EGFR/C-Met AntibodiesAugust 2021November 2023Abandon2730NoNo
17358788METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORSJune 2021December 2024Allow4131YesNo
17303970EXPRESSION OF NOVEL CELL TAGSJune 2021August 2024Allow3831YesNo
17297847ANTI-ALK2 ANTIBODIES AND USES THEREOFMay 2021July 2025Allow5021NoNo
17290197METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITORApril 2021July 2025Allow5121YesNo
17282249CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION THROUGH SPECIFIC BINDING TO TARGET CELL, AND USE THEREOFApril 2021June 2025Abandon5011NoNo
17198229ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR AND USES THEREOFMarch 2021February 2025Allow4721NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, RUIXIANG.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
1
(33.3%)
Examiner Reversed
2
(66.7%)
Reversal Percentile
85.7%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
39
Allowed After Appeal Filing
17
(43.6%)
Not Allowed After Appeal Filing
22
(56.4%)
Filing Benefit Percentile
72.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 43.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner LI, RUIXIANG - Prosecution Strategy Guide

Executive Summary

Examiner LI, RUIXIANG works in Art Unit 1674 and has examined 243 patent applications in our dataset. With an allowance rate of 95.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner LI, RUIXIANG's allowance rate of 95.9% places them in the 85% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LI, RUIXIANG receive 2.12 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LI, RUIXIANG is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +5.6% benefit to allowance rate for applications examined by LI, RUIXIANG. This interview benefit is in the 32% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.4% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 56.9% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 92.5% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 67.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.9% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 42.4% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.